Company Overview of Stemedica Cell Technologies, Inc.
Stemedica Cell Technologies, Inc., a biopharmaceutical company, engages in the development and manufacture of adult stem cells and stem cell factors for research institutions and hospitals for pre-clinical and clinical studies. The company was incorporated in 2005 and is based in San Diego, California with a subsidiary location in Lausanne, Switzerland.
5375 Mira Sorrento Place
San Diego, CA 92121
Founded in 2005
Key Executives for Stemedica Cell Technologies, Inc.
Vice Chairman and Chief Executive Officer
President, Chief Medical Officer and Director
Chief Regulatory & Clinical Development Officer
Compensation as of Fiscal Year 2015.
Stemedica Cell Technologies, Inc. Key Developments
FDA Grants Investigational New Drug Approval for Phase IIa Clinical Trial Using Stemedica Cell Technologies, Inc.'s itMSC Therapy to Treat Alzheimer's Disease
Jun 9 15
Stemedica Cell Technologies, Inc. received the FDA's investigational new drug approval for a United States-based, Phase IIa clinical study using its allogeneic stem-cell therapy to treat subjects with mild to moderate dementia due to Alzheimer's disease (AD). The study is sponsored by Stemedica International, S.A. and will start at the University of California, San Diego (UCSD) under Principle Investigator Douglas Galasko, M.D. and expand to other sites. Stemedica International will provide management and financial support for this clinical trial. The clinical trial is titled 'A Phase IIa Multicenter, Randomized, Single-blind, Placebo-controlled, Crossover Study to Assess the Safety, Tolerability, and Preliminary Efficacy of a Single Intravenous Dose of Allogeneic Human Mesenchymal Stem Cells in Subjects with Mild to Moderate Dementia Due to Alzheimer's Disease.' Stemedica's bone marrow-derived, allogeneic itMSCs are unique because they are grown under hypoxic conditions that more closely resemble the environment in which they live in the body. Compared to other MSCs, itMSCs secrete higher levels of growth factors usually associated with angiogenesis and healing. Stemedica International's AD stem cell therapies feature itMSCs, neural stem cells (NSCs) and stem cell factors. Promising results were achieved during a three-year, intensive, pre-clinical research project supported by a grant from the Swiss Commission for Technology and Innovation (CTI). The research was conducted at the Laboratoire d'Optique Biomedicale headed by Professor Theo Lasser at École Polytechnique Fédérale de Lausanne (EPFL) in Switzerland. Stemedica International's pre-clinical research was led by Chief Scientist Tristan Bolmont, Ph.D. To evaluate the impact of an intravenous delivery of human mesenchymal stem cells on amyloid pathology, the well-established APPPS1 transgenic mouse model of Alzheimer's disease was used. Intravenous delivery of itMSC safely reduced cerebral Abeta pathology in APPPS1 animals analyzed one week after the last injection. Both aged and young APPPS1 mice exhibited significantly decreased Abeta amyloidosis following the itMSC treatments. Concomitantly, microglial activation was diminished in aged and young itMSC-treated APPPS1 mice. No increase of vascular amyloid or manifestation of microhemorrhages was observed following the repeated intravenous itMSC delivery. Biodistribution analysis revealed that intravenously delivered itMSC migrate to the brain and could be detected in this organ with the high value at one hour post-delivery, decreasing after one day and subsequently dropping below detection level at one week after the injection.
Stemedica Cell Technologies, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 03:00 PM
Apr 6 15
Stemedica Cell Technologies, Inc. Presents at Needham & Company's 14th Annual Healthcare Conference, Apr-14-2015 03:00 PM. Venue: Westin Grand Central Hotel, New York, New York, United States.
Stemedica Cell Technologies Appoints Mahendra Rao to its Scientific and Medical Advisory Board
Apr 8 14
Stemedica Cell Technologies Inc. welcomed to its Scientific and Medical Advisory Board prominent stem cell and regenerative medicine expert Dr. Mahendra Rao, M.D., Ph.D. As a Founding Director of the National Institute of Health (NIH) Center for Regenerative Medicine (CRM), he has built the Center into a world-class organization recognized for its excellence in the clinical translation of stem cell technology, and his expertise will help Stemedica shape its strategy to meet global demand for its stem cell technology.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|